Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Zehra Kaymakcalan"'
Autor:
Yonghao Cao, Bohdan P. Harvey, Liang Jin, Susan Westmoreland, Jing Wang, Munish Puri, Yingli Yang, Holly M. Robb, Sultan Tanriverdi, Chenqi Hu, Xue Wang, Xiaofeng Xin, Yingchun Liu, Michael P. Macoritto, Kathleen M. Smith, Yu Tian, Kevin White, Timothy R.D.J. Radstake, Zehra Kaymakcalan
Publikováno v:
JID Innovations, Vol 4, Iss 1, Pp 100250- (2024)
Adalimumab but neither etanercept nor certolizumab-pegol has been reported to induce a wound-healing profile in vitro by regulating macrophage differentiation and matrix metalloproteinase expression, which may underlie the differences in efficacy bet
Externí odkaz:
https://doaj.org/article/655145936f1542ad926ac42c32f1ff28
Background Anti-TNF therapies are effective at preventing inflammation and structural damage in rheumatoid arthritis (RA). However, the role of TNF in cartilage destruction in RA is not well understood. Therefore, we studied the effects of TNF on car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f978c95ba552915cb588785cd05b47
https://doi.org/10.21203/rs.2.20348/v1
https://doi.org/10.21203/rs.2.20348/v1
Autor:
Michael Siedler, Stylianos Michalakis, Angelika Freitag, John F. Carpenter, Theodore W. Randolph, Julia Engert, Martin Biel, Maliheh Shomali, Gerhard Winter, Zehra Kaymakcalan
Publikováno v:
Pharmaceutical Research. 32:430-444
The potential contribution of protein aggregates to the unwanted immunogenicity of protein pharmaceuticals is a major concern. In the present study a murine monoclonal antibody was utilized to study the immunogenicity of different types of aggregates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9412980ea3e424b08b83def6db9e6380
https://doi.org/10.1007/s11095-014-1472-6
https://doi.org/10.1007/s11095-014-1472-6
Autor:
Maliheh Shomali, Julia Engert, Angelika Freitag, John F. Carpenter, Theodore W. Randolph, Zehra Kaymakcalan, Michael Siedler, Gerhard Winter, Sultan Tanriverdi
Publikováno v:
Journal of pharmaceutical sciences. 104(5)
Dosage levels and particulate contents of therapeutic protein formulations are potential factors that impact immunogenicity of protein therapeutics. Here, we evaluated the effect of dose levels on the immunogenicity of protein particulates formed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd95bf00476ffa8df8b63f10181dbfd0
https://pubmed.ncbi.nlm.nih.gov/25737325
https://pubmed.ncbi.nlm.nih.gov/25737325
Autor:
John F. Carpenter, Zehra Kaymakcalan, Michael Siedler, Theodore W. Randolph, Maliheh Shomali, Julia Engert, Gerhard Winter, Angelika Freitag
Publikováno v:
Journal of pharmaceutical sciences. 103(1)
Immunogenicity of therapeutic monoclonal antibodies (mAbs) is a concern because of the effects of anti-drug antibodies (ADAs) on therapeutic efficacy. Particulate matter has been suggested as a potential contributing factor to immunogenicity. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c756358cc54f56f0473b730af8d9f53
https://pubmed.ncbi.nlm.nih.gov/24227137
https://pubmed.ncbi.nlm.nih.gov/24227137
Publikováno v:
Current Protocols in Pharmacology
The number of therapeutic antibodies approved by regulatory agencies as novel drugs and the number of antibodies in development has increased significantly. The modular nature of antibody structure has enabled researchers to more predictably design t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ce0f4d814158b8554c17f14c4a609e
https://pubmed.ncbi.nlm.nih.gov/22294129
https://pubmed.ncbi.nlm.nih.gov/22294129
Autor:
Jochen G. Salfeld, Renee M. Miller, Zehra Kaymakcalan, Leena Kalghatgi, Geertruida M. Veldman
Publikováno v:
Antibody Engineering ISBN: 9783642011436
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8718ba5fe5c575e3bdd6914ed657e366
https://doi.org/10.1007/978-3-642-01144-3_46
https://doi.org/10.1007/978-3-642-01144-3_46
Publikováno v:
Antibody Engineering ISBN: 9783642011436
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e96997b03dafe2bad69f48bc073ebc7
https://doi.org/10.1007/978-3-642-01144-3_19
https://doi.org/10.1007/978-3-642-01144-3_19
Autor:
Denise Karaoglu Hanzatian, Limin Xiong, Eric H. Sasso, Sahana Bose, Susanne Scesney, Zehra Kaymakcalan, Paul Sakorafas, Jochen G. Salfeld
Publikováno v:
Clinical immunology (Orlando, Fla.). 131(2)
The TNF antagonists adalimumab, infliximab, and etanercept are effective treatments for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis, but only adalimumab and infliximab have been found to be efficacious in Crohn's
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855ed89e09174f07bc45a1cd2f3864de
https://pubmed.ncbi.nlm.nih.gov/19188093
https://pubmed.ncbi.nlm.nih.gov/19188093
Publikováno v:
Clinical Immunology. 131:S71-S72
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de7624313431ac4a34de89c20f03d5d6
https://doi.org/10.1016/j.clim.2009.03.209
https://doi.org/10.1016/j.clim.2009.03.209